Intraperitoneal treatment of malignant ascites due to epithelial tumors with catumaxomab: A phase II/III study

被引：1
|
作者：
Parsons, S.
Murawa, P. X.
Koralewski, P.
Kutarska, E.
Kolesnik, O. O.
Stroehlein, M. A.
Lahr, A.
Jaeger, M.
Heiss, M. M.
机构：
[1] City Hosp Nottingham, Nottingham, England
[2] Oddzial Chirurg Onkol, Poznan, Poland
[3] Oddzial Chemioterapii Wojewodzki, Krakow, Poland
[4] Oddzial III Onkol Ginekol, Lublin, Poland
[5] Inst Oncol Acad Med Sci, Kiev, Ukraine
[6] Klinikum Koeln Merheim, Cologne, Germany
[7] Fresenius Biotech GmbH, Munich, Germany
[8] TRION Res GmbH, Martinsried, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3000
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Treatment with the trifunctional antibody catumaxomab followed by systemic chemotherapy: Results of a subgroup analysis from a phase III study in patients with relapsed ovarian cancer and malignant ascites
    Chekerov, R.
    Wimberger, P.
    Vergote, I.
    Schneeweiss, A.
    Scambia, G.
    Colombo, N.
    Guastalla, J. P.
    Lordick, F.
    Schulze, E.
    Sehouli, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S742 - S742
  • [42] Catumaxomab therapy eliminates putative CD133+EpCAM+ cancer stem celles from malignant ascites: data from a pivotal phase II/III study
    Lindhofer, H.
    Schoberth, A.
    Pelster, D.
    Hess, J.
    Herold, J.
    Jaeger, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 142 - 142
  • [43] Prolonged Ascites Symptom-free Time in Patients With Malignant Ascites After Treatment With Catumaxomab
    Schulze, E.
    Parsons, S. L.
    Heiss, M. M.
    Hennig, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S245 - S246
  • [44] Follow-up results from a phase II/III study of catumaxomab in patients with malignant ascites: evaluating relative lymphocyte count as a potential biomarker for overall survival
    Heiss, M.
    Stroehlein, M. A.
    Bokemeyer, C.
    Arnold, D.
    Parsons, S. L.
    Ott, M. G.
    Schulze, E.
    Lindhofer, H.
    Seimetz, D.
    Hennig, M.
    ONKOLOGIE, 2011, 34 : 169 - 170
  • [45] Immunomonitoring Results of a Phase II/III Study of Malignant Ascites Patients Treated with the Trifunctional Antibody Catumaxomab (Anti-EpCAM x Anti-CD3)
    Jaeger, Michael
    Schoberth, Alexandra
    Ruf, Peter
    Hess, Juergen
    Hennig, Michael
    Schmalfeldt, Barbara
    Wimberger, Pauline
    Stroehlein, Michael
    Theissen, Bettina
    Heiss, Markus M.
    Lindhofer, Horst
    CANCER RESEARCH, 2012, 72 (01) : 24 - 32
  • [46] Prolonged ascites symptom-free time in patients with malignant ascites after treatment with catumaxomab
    Schulze, E.
    Parsons, S. L.
    Heiss, M. M.
    Wimberger, P.
    Hennig, M.
    ONKOLOGIE, 2011, 34 : 167 - 168
  • [47] Immunomonitoring results of a pivotal phase II/III study with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) in patients with malignant ascites
    Jaeger, M.
    Schoberth, A.
    Hennig, M.
    Burges, A.
    Heiss, M.
    Wimberger, P.
    Schmalfeldt, B.
    Lindhofer, H.
    ONKOLOGIE, 2010, 33 : 158 - 158
  • [48] MAINTENANCE OF QUALITY OF LIFE IN PATIENTS WITH MALIGNANT ASCITES DURING TREATMENT WITH THE TRIFUNCTIONAL ANTIBODY CATUMAXOMAB: RESULTS FROM THE PHASE III B CASIMAS TRIAL
    Lordick, F.
    Sehouli, J.
    Vergote, I. B.
    Rosenberg, P.
    Schneeweiss, A.
    Block, A.
    Salat, C.
    Scambia, G.
    Berton-Rigaud, D.
    Wimberger, P.
    ANNALS OF ONCOLOGY, 2012, 23 : 514 - 514
  • [49] Pooled analysis of two phase III studies provides prognostic indicators for clinical out-come after catumaxomab treatment for malignant ascites
    Bokemeyer, C.
    Heiss, M. M.
    Lordick, F.
    Parsons, S. L.
    Wimberger, P.
    Friccius-Quecke, H.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S212 - S213
  • [50] Catumaxomab: Pharmacodynamic and pharmacokinetic data from phase IIIb CASIMAS study in patients with malignant ascites.
    Rosenberg, Per
    Dudnitchenko, Alexander Serg
    Bondar, Vladimir
    Salat, Christoph
    Havsteen, Hanne
    Bokemeyer, Carsten
    Berton-Rigaud, Dominique
    Durando, Xavier
    Vergote, Ignace B.
    Wimberger, Pauline
    Lordick, Florian
    Lindhofer, Horst
    Martinius, Holger
    Sehouli, Jalid
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345